BOSTON, March 18 Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce the Company has secured the U.S. Trademark for the MammoView® name. The MamoView® Breast Endoscopy System offers a state-of-the-art endoscopic technology for detecting early stage breast cancer. The Company's Breast Endoscopy System employs advanced micro endoscopes and optical technology to give physicians sharp, clear images of the milk ducts, where the majority of breast cancers arise. This equipment will distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods. It performs related intraductal procedures with direct visualization of tissues. In addition, it complements existing diagnosis and treatment with direct endoscopic observation.
Solos Endoscopy, Inc was granted the U.S. trademark registration # 3637510 for the protection of the MammoView® name. A registered trademark on the USPTO's principal register grants a bundle of exclusive rights upon the registered owner, including the right to exclusive use of the mark in relation to the products or services for which it is registered. The law in most jurisdictions also allows the owner of a registered trademark to prevent unauthorized use of the mark in relation to products or services that are identical or "colorfully" similar to the "registered" products or services, and in certain cases, prevent use in relation to entirely dissimilar products or services.
"Securing the trademark for the MammoView brand is a significant asset to the company," stated Bob Segersten CEO of Solos Endoscopy, Inc. " This is not only important to our business domestically, but as we continue or work in achieving the CE Mark, this registration can be used as a basis for obtaining registration in other countries."
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE Solos Endoscopy, Inc.